WuXi Biologics (2269.HK), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Tuesday that, in recognition of its continued efforts and performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best-in-Class World Index (DJ BIC World) and the Dow Jones Best-in-Class Emerging Markets Index (DJ BIC Emerging Markets).
Through S&P Global's Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index are claimed to identify sustainability leaders that rank in the top 10 percent based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.
Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally within its industry, and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.
WuXi Biologics named in 2026 Dow Jones Best-in-Class World Index and Emerging Markets Index
Clearway Health recognised with 2026 Great Place To Work Certification for fourth consecutive year
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Insilico Medicine enters strategic collaboration agreement with Ribo
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954
Avid Bioservices names new chief commercial officer
AnaCardio reports Phase 1b/2a data showing cardiac function gains with AC01
Inhibrx reports positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
Oncopeptides plans EMA filing to broaden Pepaxti indication
GSK partners with SBP Group to accelerate China launch of bepirovirsen
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial